Flow cytometric analysis of micronuclei in mammalian cell cultures: past, present and future

被引：46

作者：

Avlasevich, Svetlana ^{[1
]}

Bryce, Steven ^{[1
]}

De Boeck, Marlies ^{[2
]}

Elhajouji, Azeddine ^{[3
]}

Van Goethem, Freddy ^{[2
]}

Lynch, Anthony ^{[4
]}

Nicolette, John ^{[5
]}

Shi, Jing ^{[6
]}

Dertinger, Stephen ^{[1
]}

机构：

[1] Litron Labs, Rochester, NY 14623 USA

[2] Janssen Pharmaceut NV, Genet & Exploratory Toxicol, Johnson & Johnson Pharmaceut R&D, B-2340 Beerse, Belgium

[3] Novartis Inst Biomed Res, CH-4002 Basel, Switzerland

[4] GlaxoSmithKline R&D 3F02, Ware, Herts, England

[5] Abbott Labs, Abbott Pk, IL 60064 USA

[6] BioReliance Corp, Rockville, MD 20850 USA

来源：

MUTAGENESIS | 2011年 / 26卷 / 01期

关键词：

IN-VITRO; HUMAN-LYMPHOCYTES; CHROMOSOMAL DAMAGE; ANEUGENIC ACTIVITY; ABERRATION ASSAY; IMAGE-ANALYSIS; CYTOTOXICITY; IRRADIATION; VALIDATION; PROBES;

D O I：

10.1093/mutage/geq058

中图分类号：

Q3 [遗传学];

学科分类号：

071007 ; 090102 ;

摘要：

The relative simplicity of the in vitro micronucleus (MNvit) endpoint has made it amenable to several automated scoring approaches. Flow cytometry is one such scoring platform that has been successfully employed. This review describes the origins of the MNvit assay, as well as the evolution and properties of flow cytometry-based scoring systems. While the current state-of-the-art methods acquire micronucleus (MN) frequency data very efficiently, it is becoming clear that they also endow the assay with high information content. For instance, simultaneous with MN frequency determinations, several additional endpoints are acquired that provide insights into cytotoxicity, cell cycle perturbations and, in the event of MN induction, information about genotoxic mode of action. This review concludes with a discussion regarding data gaps and also recommendations for additional work that is needed to more fully realise the potential of flow cytometric MNvit scoring.

引用

页码：147 / 152

页数：6

共 57 条

[31] Concordance Analysis of an In Vitro Micronucleus Screening Assay and the Regulatory Chromosome Aberration Assay Using Pharmaceutical Drug Candidates [J].